Pericarditis recurrente

  1. Otero García, O. 1
  2. Abou-Jokh Casas, C. 1
  3. Martínez Monzonís, A. 2
  4. González Ferrero, T. 1
  5. González Juanetey, J.R. 2
  1. 1 Servicio de Cardiología. Hospital Clínico Universitario de Santiago de Compostela. Santiago de Compostela. La Coruña, España
  2. 2 Servicio de Cardiología. Hospital Clínico Universitario de Santiago de Compostela. Santiago de Compostela. La Coruña, España Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV)
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2021

Título do exemplar: Enfermedades cardiovasculares (IX)

Serie: 13

Número: 43

Páxinas: 2532-2539

Tipo: Artigo

DOI: 10.1016/J.MED.2021.10.004 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Obxectivos de Desenvolvemento Sustentable

Resumo

Recurrent pericarditis is pericarditis in which there is evidence of a new pericarditis episode following a symptoms-free period of at least four to six weeks following an initial diagnosis of acute pericarditis. The recurrence rate varies and it can occur in up to half of cases following a first recurrence in patients who receive inadequate treatment. The pathophysiology is controversial. It has been postulated that an infectious agent may trigger an autoimmune or autoinflammatory response in susceptible patients. The diagnostic criteria do not differ greatly from those used to diagnose an initial episode of acute pericarditis and treatment is able to be added to the treatment for the initial episode. However, in the case of multiple recurrences, other treatment options must be taken into account, included glucocorticoids and immunosuppressive agents and, as a last option, a pericardiectomy.

Referencias bibliográficas

  • Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J. 2015 ESC Guidelines for the diagnosis and mana-gement of pericardial diseases. Eur Heart J. 2015;36(42):2921-64.
  • Cremer PC, Kumar A, Kontzias A, Tan CD, Rodriguez ER, Imazio M. Complicated pericarditis: Understanding risk factors and pathophysiology to inform imaging and treatment. J Am Coll Cardiol. 2016;68(21): 2311-28.
  • Soler Soler J, Sagrista Sauleda J, Permanyer Miralda G. Relapsing pericarditis. Heart. 2004;90(11):1364-8.
  • Pankuweit S, Stein A, Karatolios K, Richter A, Ruppert V, Maisch B. Viral genomes in the pericardial fluid and in peri- and epicardial biopsies from a German cohort of patients with large to moderate pericardial effusions. Heart Fail Rev. 2013;18(3):329-36.
  • Imazio M, Brucato A, DeRosa F, Lestuzzi C, Bombana E, Scipione F. Aetiological diagnosis in acute and recurrent pericarditis: when and how. J Cardiovasc Med. 2009;10(3):217-30.
  • Brucato A, Valenti A, Maisch B. Acute and recurrent pericarditis. J Am Coll Cardiol. 2017;69(22):2775.
  • Imazio M, Cecchi E, Demichelis B, Ierna S, Demarie D, Ghisio A. Indicators of poor prognosis of acute pericarditis. Circulation. 2007; 115(21):2739-44.
  • Imazio M, Gaita F, LeWinter M. Evaluation and treatment of pericarditis. JAMA. 2015;314(14):1498-506.
  • Fowler NO, Harbin AD 3rd. Recurrent acute pericarditis: follow-up study of 31 patients. J Am Coll Cardiol. 1986;7(2):300-5.
  • Cacoub P, Marques C. Acute recurrent pericarditis: from pathophysiology towards new treatment strategy. Heart. 2020;106(14):1046-51.
  • Maestroni S, Di Corato PR, Cumetti D, Chiara DB, Ghidoni S, Prisaca-ru L. Recurrent pericarditis: autoimmune or autoinflammatory? Autoimmun Rev. 2012;12(1):60-5.
  • Ozen S, Demirkaya E, Amaryan G, Koné-Paut I, Polat A, Woo P. Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Dis. 2014;73(4):662-7.
  • Muruve DA, Pétrilli V, Zaiss AK, White LR, Clark SA, Ross PJ. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature. 2008;452(7183):103-7.
  • Tombetti E, Giani T, Brucato A, Cimaz R. Recurrent pericarditis in children and adolescents. Front Pediatr. 2019;7:419.
  • Soler Soler J. Relapsing pericarditis. Heart. 2004;90(11):1364-68.
  • Dauphin C, Merlin E, Chalard A, Trésorier R, Lusson J, Soubrier M. Recurrent pericarditis: current challenges and future prospects. Clin Cardiol. 2016;7:99-108.
  • Imazio M, Demichelis B, Parrini I, Cecchi E, Pomari F, Demarie D. Recurrent pain without objective evidence of disease in patients with pre-vious idiopathic or viral acute pericarditis. Am J Cardiol. 2004;94(7): 973-5.
  • Imazio M, Brucato A, Maestroni S, Cumetti D, Belli R, Trinchero R. Risk of constrictive pericarditis after acute pericarditis. Circulation. 2011;124(11):1270-5.
  • Imazio M, Brucato A, Adler Y, Brambilla G, Artom G, Cecchi E. Prognosis of idiopathic recurrent pericarditis as determined from pre-viously published reports. Am J Cardiol. 2007;100(6):1026-8.
  • Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2020;42(1):17-96.
  • Imazio M, Brucato A, Mayosi BM, Derosa FG, Lestuzzi C, MacOr A. Medical therapy of pericardial diseases: part I: idiopathic and infec-tious pericarditis. J Cardiovasc Med. 2010;11(10):712-22.
  • Alabed S, Cabello JB, Irving GJ, Qintar M, Burls A. Colchicine for pericarditis. Cochrane Database Syst Rev. 2014;(8):CD010652.
  • Verma S, Eikelboom J, Nidorf S, Al-Omran M, Gupta N, Teoh H. Colchicine in cardiac disease: a systematic review and metaanalysis of randomized controlled trials. BMC Cardiovasc Disord. 2015;15(1): 96-110.
  • Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F. Colchicine in addition to conventional therapy for acu-te pericarditis. Circulation. 2005;112(13):2012-16.
  • Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F. A Randomized Trial of Colchicine for Acute Pericarditis. N Engl J Med. 2013;369(16):1522-28.
  • Imazio M, Bobbio M, Cecchi E, Demarie D, Pomari F, Moratti M. Colchicine as first-choice therapy for recurrent pericardi-tis. Arch Intern Med. 2005;165(17):1987-91.
  • Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S. Colchicine for recurrent pericarditis (CORP). Ann Intern Med. 2011;155(7):409-14.
  • Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double blind, placebo controlled, randomised trial. Lancet. 2014;383(9936):2232-37.
  • Sambola A, Roca Luque I, Mercé J, Alguersuari J, Francisco Pascual J, García Dorado D. Colchicine administered in the first episode of acute idiopathic pericarditis: A randomized multicenter open label study. Rev Esp Cardiol (English Edition). 2019; 72(9):709-16.
  • Imazio M, Brucato A, Adler Y, Brambilla G, Artom G, Cecchi E. Prognosis of idiopathic recurrent pericarditis as determined from pre-viously published reports. Am J Cardiol. 2007;100(6):1026-28.
  • Maisch B, Ristic ́ AD, Pankuweit S. Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone: the way to avoid side effects of systemic corticosteroid therapy. Eur Heart J. 2002;23(19): 1503-8.
  • Vianello F, Cinetto F, Cavraro M, Battisti A, Castelli M, Imbergamo S. Azathioprine in isolated recurrent pericarditis: a single centre experience. Int J Cardiol. 2011;147(3):477-8.
  • Peiffer Smadja N, Savey L, Domont F. Steroids and immunosuppressive agents in idiopathic refractory recurrent pericarditis: a single center experience. Rev Med Interne. 2017;38S:A81-A82-CO055.
  • March CJ, Mosley B, Larsen A, Cerretti DP, Braedt G, Price V. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature. 1985;315(6021):641-7.
  • Picco P, Briscan G, Traverso F, Loy A, Gattorno M, Martini A. Successful treatment of idiopathic recurrent pericarditis in children with interleukin 1beta receptor antagonist (anakinra): an unrecognized autoin-flammatory disease? Arthritis Rheum. 2009;60(1):264-68.
  • Jain S, Thongprayoon C, Espinosa RE, Hayes SN, Klarich KW, Cooper LT. Effectiveness and safety of anakinra for management of refractory pericarditis. Am J Cardiol. 2015;116(8):1277-9.
  • Betancourt B, Ombrello A, Subedi A, Hoffmann PM, Kastner DL. Recurrent pericarditis: A challenge in autoinflammatory disease clinic and the role of anakinra [abstract]. Arthritis Rheumatol. 2018;70Suppl10.
  • Lazaros G, Imazio M, Brucato A, Vassilopoulos D, Vaileiou P, Gattorno M. Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of published evidence. J Cardiovasc Med. 2016;17(4):256-62.
  • Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence. JAMA. 2016;316(18):1906-12.
  • Imazio M, Andreis A, De Ferrari G, Cremer P, Mardigyan V, Maestroni S. Anakinra for corticosteroid dependent and colchicine resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. Eur J Prev Cardiol. 2020;27(9): 956-64.
  • Klein AL, Lin D, Cremer PC, Nasir S, Luis SA, Abbate A. Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial. Heart. 2020;107(6):488-96.
  • Klein A, Imazio M, Cremer P, Brucato A, Abbate A, Fang F. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med. 2021;384(1):31-41.
  • Lazaros G, Antonatou K, Vassilopoulos D. The therapeutic role of interleukin-1 inhibition in idiopathic recurrent pericarditis: Current evidence and future challenges. Front Med (Lausanne). 2017;4:78.
  • Kougkas N, Fanouriakis A, Papalopoulos I, Bertsias G, Avgoustidis N, Repa A. Canakinumab for recurrent rheumatic disease associated pericarditis: a case series with long term follow- up. Rheumatology. 2018;57(8):1494-5.
  • Epçaçan S, Sahin S, Kasapcopur O. Anaphylactic reaction to anakinra in a child with steroid dependent idiopathic recurrent pericarditis and successful management with canakinumab. Cardiol Young. 2019;29(4): 549-51.
  • Moretti M, Buiatti A, Merlo M, Massa L, Fabris E, Pinamonti B. Usefulness of high dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis. Am J Cardiol. 2013;112(9):1493-8.
  • Khandaker MH, Schaff HV, Greason KL, Anavekar NS, Espinosa RE, Hayes SN. Pericardiectomy vs medical management in patients with relapsing pericarditis. Mayo Clin Proc. 2012;87(11):1062-70.
Fonte de datos: Dialnet